SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001811764-22-000026
Filing Date
2022-03-25
Accepted
2022-03-25 08:22:46
Documents
14
Period of Report
2022-03-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pnt-20220325.htm   iXBRL 8-K 37847
2 EX-99.1 fiscal2021earningsrelease.htm EX-99.1 116090
6 image_0a.jpg GRAPHIC 48379
  Complete submission text file 0001811764-22-000026.txt   372657

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pnt-20220325.xsd EX-101.SCH 1917
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pnt-20220325_lab.xml EX-101.LAB 23874
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pnt-20220325_pre.xml EX-101.PRE 12531
8 EXTRACTED XBRL INSTANCE DOCUMENT pnt-20220325_htm.xml XML 11210
Mailing Address 4850 WEST 78TH STREET INDIANAPOLIS IN 46268
Business Address 4850 WEST 78TH STREET INDIANAPOLIS IN 46268 (647) 401-2182
POINT Biopharma Global Inc. (Filer) CIK: 0001811764 (see all company filings)

IRS No.: 850800493 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39373 | Film No.: 22768303
SIC: 2834 Pharmaceutical Preparations